We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Bayview

News List

Emergent Pledges FDA Improvements at Troubled Vaccine Plant firstwordpharma
June 15, 2021
Emergent BioSolutions is promising the FDA a series of fixes in response to an inspection that led to production stopping at the company's Bayview facility in Baltimore, which had been making Johnson & Johnson's COVID-19 vaccine, reported Bloomberg.
Further woes for Emergent’s Bayview vaccine production facility europeanpharmaceuticalreview
April 26, 2021
An FDA inspection identified nine concerns including unsanitary conditions and ineffective practices for preventing cross-contamination at Emergent’s facility.
FDA halts COVID-19 vaccine production at Emergent facility europeanpharmaceuticalreview
April 22, 2021
The FDA has requested Emergent’s Bayview plant be closed and vaccine production halted while the agency investigates potential good manufacturing practice (GMP) violations.
Millions of J&J Covid-19 vaccine doses scrapped after US ingredient mix-up pharmaceutical-technology
April 02, 2021
Up to 15 million doses of Johnson & Johnson’s (J&J) Covid-19 vaccine have been ruined due to a mix-up with ingredients at a US production plant.